Los Angeles Capital Management LLC Has $816,000 Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Los Angeles Capital Management LLC boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 27.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,344 shares of the company’s stock after purchasing an additional 2,219 shares during the quarter. Los Angeles Capital Management LLC’s holdings in TransMedics Group were worth $816,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of TMDX. Cutler Group LLC CA raised its position in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after buying an additional 600 shares in the last quarter. RiverPark Advisors LLC acquired a new position in TransMedics Group in the 3rd quarter valued at $60,000. First Horizon Advisors Inc. lifted its position in shares of TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after acquiring an additional 222 shares during the period. Van ECK Associates Corp increased its position in shares of TransMedics Group by 39.0% in the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock worth $116,000 after purchasing an additional 597 shares during the period. Finally, Headlands Technologies LLC acquired a new position in TransMedics Group in the third quarter valued at about $180,000. Institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 30,000 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $130.07, for a total transaction of $3,902,100.00. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 30,000 shares of the company’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $130.07, for a total value of $3,902,100.00. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,017,905.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Stephen Gordon sold 15,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the transaction, the chief financial officer now owns 23,299 shares of the company’s stock, valued at $1,724,358.99. The disclosure for this sale can be found here. Insiders have sold a total of 295,889 shares of company stock worth $31,623,584 in the last ninety days. Company insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 1.2 %

Shares of NASDAQ:TMDX opened at $128.77 on Friday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $132.96. The company has a market capitalization of $4.24 billion, a PE ratio of -378.74 and a beta of 1.87. The company has a fifty day moving average of $89.25 and a 200-day moving average of $79.26.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business’s quarterly revenue was up 132.9% on a year-over-year basis. During the same period last year, the company earned ($0.08) earnings per share. On average, equities analysts predict that TransMedics Group, Inc. will post 0.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TMDX. Oppenheimer increased their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. raised their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $120.00 price target (up previously from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $119.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.